Literature DB >> 32975467

Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.

Shubha Priyamvada1, Anoop Kumar1,2, Seema Saksena1,2, Hayat Onyuksel3.   

Abstract

Aim: To evaluate the efficacy of locally delivered nanomedicine, vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) to the colon and conduct in vitro release studies of a potential oral formulation. Materials & methods: Intracolonic instillation of VIP-SSM was tested in a mouse model of dextran sulfate sodium-induced colitis. Based on the effective mouse dose, human equivalent dose containing nanomedicine powder was filled into enteric coated capsules for in vitro release testing.
Results: Colonic delivery of VIP-SSM significantly alleviated colitis. VIP-SSM containing capsules completely dissolved at colonic pH allowing micelles to reform with active VIP. Capsule formulations exhibited reproducible release profiles when stored up to 6 weeks demonstrating stability.
Conclusion: VIP-SSM is an effective nanomedicine formulation which appears to have potential for oral treatment of colitis in humans. [Formula: see text].

Entities:  

Keywords:  VIP nanomedicine; colitis; colonic delivery; inflammatory bowel disease; oral capsule form; oral nanomedicine; slc26a3; sterically stabilized micelles; targeted delivery

Mesh:

Substances:

Year:  2020        PMID: 32975467      PMCID: PMC7713900          DOI: 10.2217/nnm-2020-0280

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  47 in total

Review 1.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.

Authors:  Anne des Rieux; Virginie Fievez; Marie Garinot; Yves-Jacques Schneider; Véronique Préat
Journal:  J Control Release       Date:  2006-08-23       Impact factor: 9.776

2.  GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.

Authors:  Xinfu Guan; Heidi E Karpen; John Stephens; John T Bukowski; Sanyong Niu; Guangcheng Zhang; Barbara Stoll; Milton J Finegold; Jens J Holst; Darryl Hadsell; Darry L Hadsell; Buford L Nichols; Douglas G Burrin
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

Review 3.  Improvement of drug safety by the use of lipid-based nanocarriers.

Authors:  Sok Bee Lim; Amrita Banerjee; Hayat Önyüksel
Journal:  J Control Release       Date:  2012-06-12       Impact factor: 9.776

Review 4.  Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.

Authors:  Bo Xiao; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2012-10-05       Impact factor: 6.648

5.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

6.  Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.

Authors:  Hamed Laroui; Guillaume Dalmasso; Hang Thi Thu Nguyen; Yutao Yan; Shanthi V Sitaraman; Didier Merlin
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

7.  Distribution of mesalamine enemas in patients with active distal ulcerative colitis.

Authors:  N J Chapman; M L Brown; S F Phillips; W J Tremaine; K W Schroeder; M K Dewanjee; A R Zinsmeister
Journal:  Mayo Clin Proc       Date:  1992-03       Impact factor: 7.616

Review 8.  Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.

Authors:  Susan Hua; Ellen Marks; Jennifer J Schneider; Simon Keely
Journal:  Nanomedicine       Date:  2015-03-14       Impact factor: 5.307

9.  Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA.

Authors:  Emilie Viennois; Fengyuan Chen; Hamed Laroui; Mark T Baker; Didier Merlin
Journal:  BMC Res Notes       Date:  2013-09-08

10.  A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota.

Authors:  Chenwen Li; Yang Zhao; Juan Cheng; Jiawei Guo; Qixiong Zhang; Xiangjun Zhang; Jiong Ren; Fengchao Wang; Jun Huang; Houyuan Hu; Ruibing Wang; Jianxiang Zhang
Journal:  Adv Sci (Weinh)       Date:  2019-08-01       Impact factor: 16.806

View more
  1 in total

Review 1.  Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment.

Authors:  Wunan Zhang; Cecilia Bohns Michalowski; Ana Beloqui
Journal:  Front Bioeng Biotechnol       Date:  2021-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.